In addition, it is worth noting that IL-1R1 is currently undergoing clinical trials for diseases such as rheumatoid arthritis, hydradenitis supurativa, pulmonary arterial hypertension, melanoma, etc and it is predicted that IL-1R1 can serve as a target for drugs such as thalidomide CTD 00006858, ciglitazone CTD 00001835, 5-fluorouracil BOSS, puromycin HL60 UP, and mebendazole HL60 UP. This evidence concerns the gene IL1R1 and pulmonary arterial hypertension.